Format

Send to

Choose Destination
See comment in PubMed Commons below
J Occup Environ Med. 2008 Nov;50(11):1261-72. doi: 10.1097/JOM.0b013e318181b8ca.

The direct and indirect cost burden of Crohn's disease and ulcerative colitis.

Author information

1
Thomson Healthcare, Research Division, Ann Arbor, Mich 48108, USA. teresa.gibson@thomson.com

Abstract

OBJECTIVE:

To estimate the direct medical and indirect (absenteeism and short-term disability) cost burden of Crohn's Disease (CD) and Ulcerative Colitis (UC).

METHODS:

Data were obtained from 1999 to 2005 MarketScan databases. Twelve-month expenditures for patients with CD and UC were compared to expenditures among an equal number of propensity score matched comparison group patients. Regression analysis controlled for demographics and case-mix.

RESULTS:

Annual medical expenditures were significantly higher for commercially insured CD and UC patients compared to matched comparison group patients ($18,963 vs $5300 for CD patients, $15,020 vs $4982 for UC patients, respectively, all P < 0.001). Indirect costs were also high for employed patients with these conditions.

CONCLUSIONS:

CD and UC are costly diseases with a significant cost burden related to health care utilization and productivity loss.

PMID:
19001952
DOI:
10.1097/JOM.0b013e318181b8ca
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center